AN2 Therapeutics Inc (ANTX)
2.23
-0.04
(-1.76%)
USD |
NASDAQ |
May 20, 16:00
2.22
-0.01
(-0.45%)
After-Hours: 20:00
AN2 Therapeutics Cash and Short Term Investments (Quarterly): 114.21M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 114.21M |
| December 31, 2023 | 107.30M |
| September 30, 2023 | 123.82M |
| June 30, 2023 | 95.26M |
| March 31, 2023 | 88.52M |
| Date | Value |
|---|---|
| December 31, 2022 | 96.06M |
| September 30, 2022 | 104.38M |
| June 30, 2022 | 113.39M |
| March 31, 2022 | 118.35M |
| December 31, 2021 | 58.56M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
58.56M
Minimum
Dec 2021
123.82M
Maximum
Sep 2023
101.98M
Average
105.84M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Revance Therapeutics Inc | 277.07M |
| Viking Therapeutics Inc | 962.98M |
| VYNE Therapeutics Inc | 85.95M |
| Aquestive Therapeutics Inc | 95.20M |
| Humacyte Inc | 115.50M |